PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.06) per share. This is a 93.88 percent increase over losses of $(0.98) per share from the same period last year.PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.06) per share. This is a 93.88 percent increase over losses of $(0.98) per share from the same period last year.
CBAK Energy Reports Hitrans’ Sales For First Nine Months Were $97.9M
CBAK Energy Technology, Inc. (NASDAQ:CBAT) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today announced financial
